KRYS NASDAQ
Credit Risk of going bust: lower than 96% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.03 (down more than 99.9%), Krystal Biotech, Inc. would be worth roughly what it owes.
Total debt $8.9M against a stock market value of $9.28B.
Distance to default 20.15 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.4M (short-term plus half of long-term), stock volatility 37.8%; Altman Z'' 15.41. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Pittsburgh, PA 15203
US
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ROSSI DINO A | A-Award | 1,187 | $340.03 | 2026-09-14 |
| ROSSI DINO A | A-Award | 471 | — | 2026-09-14 |
| Sutherland Everett R | A-Award | 1,187 | $340.03 | 2026-09-14 |
| Sutherland Everett R | A-Award | 471 | — | 2026-09-14 |
| Mazzacco Catherine | A-Award | 1,187 | $340.03 | 2026-09-14 |